Chronic Pain Indications Will Be Harder To Come By, FDA Says
Executive Summary
A general chronic pain indication may elude Eli Lilly's Cymbalta near the finish line because FDA has changed its thinking about the evidence needed to support the claimYou may also be interested in...
Cymbalta Adds Musculoskeletal Pain Claim Despite Advisory Committee Concerns
Label for duloxetine's new use emphasizes that efficacy was shown only in patients with chronic lower back pain and osteoarthritis.
Cymbalta Chronic Pain Label: FDA Expresses Faith In Physicians' Judgment
FDA may place more faith in physician diligence to read updated labeling as it manages the risk for Eli Lilly's Cymbalta in some chronic pain indications
Cymbalta Could Get "Fairly Narrow Broad Indication" For Pain, FDA's Rappaport Says
Agency favors a claim for musculoskeletal pain, but advisory committee members suggest considering the cause, not just the location of the pain, in the indication.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: